Cargando…

Alveolar Type II Cells or Mesenchymal Stem Cells: Comparison of Two Different Cell Therapies for the Treatment of Acute Lung Injury in Rats

The use of cell therapies has recently increased for the treatment of pulmonary diseases. Mesenchymal stem/stromal cells (MSCs) and alveolar type II cells (ATII) are the main cell-based therapies used for the treatment of acute respiratory distress syndrome (ARDS). Many pre-clinical studies have sho...

Descripción completa

Detalles Bibliográficos
Autores principales: Guillamat-Prats, Raquel, Camprubí-Rimblas, Marta, Puig, Ferranda, Herrero, Raquel, Tantinyà, Neus, Serrano-Mollar, Anna, Artigas, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464506/
https://www.ncbi.nlm.nih.gov/pubmed/32751857
http://dx.doi.org/10.3390/cells9081816
_version_ 1783577381250793472
author Guillamat-Prats, Raquel
Camprubí-Rimblas, Marta
Puig, Ferranda
Herrero, Raquel
Tantinyà, Neus
Serrano-Mollar, Anna
Artigas, Antonio
author_facet Guillamat-Prats, Raquel
Camprubí-Rimblas, Marta
Puig, Ferranda
Herrero, Raquel
Tantinyà, Neus
Serrano-Mollar, Anna
Artigas, Antonio
author_sort Guillamat-Prats, Raquel
collection PubMed
description The use of cell therapies has recently increased for the treatment of pulmonary diseases. Mesenchymal stem/stromal cells (MSCs) and alveolar type II cells (ATII) are the main cell-based therapies used for the treatment of acute respiratory distress syndrome (ARDS). Many pre-clinical studies have shown that both therapies generate positive outcomes; however, the differences in the efficiency of MSCs or ATII for reducing lung damage remains to be studied. We compared the potential of both cell therapies, administering them using the same route and dose and equal time points in a sustained acute lung injury (ALI) model. We found that the MSCs and ATII cells have similar therapeutic effects when we tested them in a hydrochloric acid and lipopolysaccharide (HCl-LPS) two-hit ALI model. Both therapies were able to reduce proinflammatory cytokines, decrease neutrophil infiltration, reduce permeability, and moderate hemorrhage and interstitial edema. Although MSCs and ATII cells have been described as targeting different cellular and molecular mechanisms, our data indicates that both cell therapies are successful for the treatment of ALI, with similar beneficial results. Understanding direct cell crosstalk and the factors released from each cell will open the door to more accurate drugs being able to target specific pathways and offer new curative options for ARDS.
format Online
Article
Text
id pubmed-7464506
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74645062020-09-04 Alveolar Type II Cells or Mesenchymal Stem Cells: Comparison of Two Different Cell Therapies for the Treatment of Acute Lung Injury in Rats Guillamat-Prats, Raquel Camprubí-Rimblas, Marta Puig, Ferranda Herrero, Raquel Tantinyà, Neus Serrano-Mollar, Anna Artigas, Antonio Cells Article The use of cell therapies has recently increased for the treatment of pulmonary diseases. Mesenchymal stem/stromal cells (MSCs) and alveolar type II cells (ATII) are the main cell-based therapies used for the treatment of acute respiratory distress syndrome (ARDS). Many pre-clinical studies have shown that both therapies generate positive outcomes; however, the differences in the efficiency of MSCs or ATII for reducing lung damage remains to be studied. We compared the potential of both cell therapies, administering them using the same route and dose and equal time points in a sustained acute lung injury (ALI) model. We found that the MSCs and ATII cells have similar therapeutic effects when we tested them in a hydrochloric acid and lipopolysaccharide (HCl-LPS) two-hit ALI model. Both therapies were able to reduce proinflammatory cytokines, decrease neutrophil infiltration, reduce permeability, and moderate hemorrhage and interstitial edema. Although MSCs and ATII cells have been described as targeting different cellular and molecular mechanisms, our data indicates that both cell therapies are successful for the treatment of ALI, with similar beneficial results. Understanding direct cell crosstalk and the factors released from each cell will open the door to more accurate drugs being able to target specific pathways and offer new curative options for ARDS. MDPI 2020-07-31 /pmc/articles/PMC7464506/ /pubmed/32751857 http://dx.doi.org/10.3390/cells9081816 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Guillamat-Prats, Raquel
Camprubí-Rimblas, Marta
Puig, Ferranda
Herrero, Raquel
Tantinyà, Neus
Serrano-Mollar, Anna
Artigas, Antonio
Alveolar Type II Cells or Mesenchymal Stem Cells: Comparison of Two Different Cell Therapies for the Treatment of Acute Lung Injury in Rats
title Alveolar Type II Cells or Mesenchymal Stem Cells: Comparison of Two Different Cell Therapies for the Treatment of Acute Lung Injury in Rats
title_full Alveolar Type II Cells or Mesenchymal Stem Cells: Comparison of Two Different Cell Therapies for the Treatment of Acute Lung Injury in Rats
title_fullStr Alveolar Type II Cells or Mesenchymal Stem Cells: Comparison of Two Different Cell Therapies for the Treatment of Acute Lung Injury in Rats
title_full_unstemmed Alveolar Type II Cells or Mesenchymal Stem Cells: Comparison of Two Different Cell Therapies for the Treatment of Acute Lung Injury in Rats
title_short Alveolar Type II Cells or Mesenchymal Stem Cells: Comparison of Two Different Cell Therapies for the Treatment of Acute Lung Injury in Rats
title_sort alveolar type ii cells or mesenchymal stem cells: comparison of two different cell therapies for the treatment of acute lung injury in rats
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464506/
https://www.ncbi.nlm.nih.gov/pubmed/32751857
http://dx.doi.org/10.3390/cells9081816
work_keys_str_mv AT guillamatpratsraquel alveolartypeiicellsormesenchymalstemcellscomparisonoftwodifferentcelltherapiesforthetreatmentofacutelunginjuryinrats
AT camprubirimblasmarta alveolartypeiicellsormesenchymalstemcellscomparisonoftwodifferentcelltherapiesforthetreatmentofacutelunginjuryinrats
AT puigferranda alveolartypeiicellsormesenchymalstemcellscomparisonoftwodifferentcelltherapiesforthetreatmentofacutelunginjuryinrats
AT herreroraquel alveolartypeiicellsormesenchymalstemcellscomparisonoftwodifferentcelltherapiesforthetreatmentofacutelunginjuryinrats
AT tantinyaneus alveolartypeiicellsormesenchymalstemcellscomparisonoftwodifferentcelltherapiesforthetreatmentofacutelunginjuryinrats
AT serranomollaranna alveolartypeiicellsormesenchymalstemcellscomparisonoftwodifferentcelltherapiesforthetreatmentofacutelunginjuryinrats
AT artigasantonio alveolartypeiicellsormesenchymalstemcellscomparisonoftwodifferentcelltherapiesforthetreatmentofacutelunginjuryinrats